Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

More articles from Clinical

  • Addition of <sup>131</sup>I-MIBG to PRRT (<sup>90</sup>Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
    Open Access
    Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
    David L. Bushnell, Kellie L. Bodeker, Thomas M. O’Dorisio, Mark T. Madsen, Yusuf Menda, Stephen Graves, Gideon K.D. Zamba and M. Sue O’Dorisio
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1274-1277; DOI: https://doi.org/10.2967/jnumed.120.254987
  • SUVs Are Adequate Measures of Lesional <sup>18</sup>F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden
    You have access
    SUVs Are Adequate Measures of Lesional 18F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden
    Yves J.L. Bodar, Berend P.F. Koene, Bernard H.E. Jansen, Matthijs C.F. Cysouw, Dennie Meijer, N. Harry Hendrikse, André N. Vis, Ronald Boellaard and Daniela E. Oprea-Lager
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1264-1269; DOI: https://doi.org/10.2967/jnumed.120.260232
  • You have access
    Hypermetabolism on Pediatric PET Scans of Brain Glucose Metabolism: What Does It Signify?
    Harry T. Chugani
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1301-1306; DOI: https://doi.org/10.2967/jnumed.120.256081
  • Detection of Early Progression with <sup>18</sup>F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy
    You have access
    Detection of Early Progression with 18F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy
    Mark C. Markowski, Pedro Isaacsson Velho, Mario A. Eisenberger, Martin G. Pomper, Kenneth J. Pienta, Michael A. Gorin, Emmanuel S. Antonarakis, Samuel R. Denmeade and Steven P. Rowe
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1270-1273; DOI: https://doi.org/10.2967/jnumed.120.259226
  • Tau<sup>IQ</sup>: A Canonical Image Based Algorithm to Quantify Tau PET Scans
    You have access
    TauIQ: A Canonical Image Based Algorithm to Quantify Tau PET Scans
    Alex Whittington, Roger N. Gunn and for the Alzheimer’s Disease Neuroimaging Initiative
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1292-1300; DOI: https://doi.org/10.2967/jnumed.120.258962
  • Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker
    You have access
    Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker
    David L. Chan, Gary A. Ulaner, David Pattison, David Wyld, Rahul Ladwa, Julian Kirchner, Bob T. Li, W. Victoria Lai, Nick Pavlakis, Paul J. Roach and Dale L. Bailey
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1278-1284; DOI: https://doi.org/10.2967/jnumed.120.257659
  • Combination of Forced Diuresis with Additional Late Imaging in <sup>68</sup>Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake
    You have access
    Combination of Forced Diuresis with Additional Late Imaging in 68Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake
    Ian Alberts, Jan Niklas-Hünermund, Christos Sachpekidis, Helle Damgaard Zacho, Clemens Mingels, Lotte Dijkstra, Karl Peter Bohn, Tilman Läppchen, Eleni Gourni, Axel Rominger and Ali Afshar-Oromieh
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1252-1257; DOI: https://doi.org/10.2967/jnumed.120.257741
  • You have access
    PSMA Theranostics: Is the Time Ripe to Pave the Way to Further Tumor Entities?
    Winfried Brenner, Joachim Strobel and Vikas Prasad
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1242-1243; DOI: https://doi.org/10.2967/jnumed.121.262737
  • Head-to-Head Comparison of <sup>68</sup>Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10–Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients
    Open Access
    Head-to-Head Comparison of 68Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10–Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients
    Melline G.M. Schilham, Patrik Zamecnik, Bastiaan M. Privé, Bas Israël, Mark Rijpkema, Tom Scheenen, Jelle O. Barentsz, James Nagarajah and Martin Gotthardt
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1258-1263; DOI: https://doi.org/10.2967/jnumed.120.258541
  • Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study
    You have access
    Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study
    Caroline Bodet-Milin, Alain Faivre-Chauvet, Thomas Carlier, Catherine Ansquer, Aurore Rauscher, Eric Frampas, Frederique Toulgoat, Damien Masson, Mickael Bourgeois, Evelyne Cerato, Vincent Rohmer, Olivier Couturier, Delphine Drui, David M. Goldenberg, Robert M. Sharkey, Jacques Barbet and Francoise Kraeber-Bodere
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1221-1227; DOI: https://doi.org/10.2967/jnumed.120.252791

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 62
SNMMI

© 2025 SNMMI

Powered by HighWire